Form 4: Collegium Pharmaceutical Director Gwen A. Melincoff Receives Stock Grant

Director Gwen A. Melincoff of Collegium Pharmaceutical, Inc. reports the acquisition of 7,693 shares of common stock through a restricted stock unit (RSU) grant.

Summary

• Gwen A. Melincoff, a director at Collegium Pharmaceutical, Inc., filed a Form 4 to report changes in beneficial ownership.
• On May 16, 2024, Melincoff acquired 7,693 shares of Collegium Pharmaceutical common stock through a grant of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of the Issuer's common stock.
• The RSUs vest on May 16, 2025, contingent upon the director's continued service.
• The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
• Following the transaction, Melincoff beneficially owns 52,468 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 7

Explanation: The document indicates a standard practice of granting stock to directors, which is generally viewed positively as it aligns interests. There are no immediate negative implications.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting period of one year encourages the director's continued service with the company.

Future Outlook

The RSUs will be settled on May 16, 2025, or earlier under certain conditions, in shares of Collegium Pharmaceutical's common stock.

Industry Context

Stock grants to directors are a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• The stock grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to act in the best interests of the shareholders.

Key Dates